J. Folkman, Tumor angiogenesis: therapeutic implications, N Engl J Med, vol.285, pp.1182-1186, 1971.

D. F. Quail and J. A. Joyce, Microenvironmental regulation of tumor progression and metastasis, Nat Med, vol.19, pp.1423-1437, 2013.

N. Ferrara and R. S. Kerbel, Angiogenesis as a therapeutic target, Nature, vol.438, pp.967-974, 2005.

B. Al-husein, M. Abdalla, M. Trepte, D. L. Deremer, and P. R. Somanath, Antiangiogenic therapy for cancer: an update, Pharmacotherapy, vol.32, pp.1095-1111, 2012.

Y. Rj and M. W. Reed, Anti-angiogenic therapy: concept to clinic, Microcirculation, vol.19, pp.115-125, 2012.

J. M. Wu and C. A. Staton, Anti-angiogenic drug discovery: lessons from the past and thoughts for the future, Expert Opin Drug Discov, vol.7, pp.723-743, 2012.

R. S. Kerbel, Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents, Bioessays, vol.13, pp.31-36, 1991.

T. Boehm, J. Folkman, T. Browder, and O. Ms, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, vol.390, pp.404-407, 1997.

C. J. Sweeney, K. D. Miller, and G. W. Sledge, Resistance in the anti-angiogenic era: nay-saying or a word of caution?, Trends Mol Med, vol.9, pp.24-29, 2003.

H. J. Broxterman, J. Lankelma, and K. Hoekman, Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences, Drug Resist Updat, vol.6, pp.111-127, 2003.

S. Giuliano and G. Pagès, Mechanisms of resistance to anti-angiogenesis therapies, Biochimie, vol.95, pp.1110-1119, 2013.

L. Huang, C. Perrault, and J. Coelho-martins, Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy, J Hematol Oncol, vol.6, p.49, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00845842

K. Hida, K. Akiyama, N. Ohga, N. Maishi, and Y. Hida, Tumour endothelial cells acquire drug resistance in a tumour microenvironment, J Biochem, vol.153, pp.243-249, 2013.

E. E. Pakos and J. P. Ioannidis, The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis, Cancer, vol.98, pp.581-589, 2003.

K. Akiyama, N. Ohga, and Y. Hida, Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment, Am J Pathol, vol.180, pp.1283-1293, 2012.

H. Lage and M. Dietel, Effect of the breast-cancer resistance protein on atypical multidrug resistance, Lancet Oncol, vol.1, pp.169-175, 2000.

J. Xu, H. Peng, and J. T. Zhang, Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy, Curr Med Chem, vol.14, pp.689-701, 2007.

Z. Ni, Z. Bikadi, M. F. Rosenberg, and Q. Mao, Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)

, Curr Drug Metab, vol.11, pp.603-617, 2010.

H. C. Cooray, C. G. Blackmore, L. Maskell, and M. A. Barrand, Localisation of breast cancer resistance protein in microvessel endothelium of human brain, Neuroreport, vol.13, pp.2059-2063, 2002.

A. C. Mena, E. G. Pulido, and C. Guillén-ponce, Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib, Anticancer Drugs, vol.21, issue.1, pp.3-11, 2010.

F. Shojaei, Anti-angiogenesis therapy in cancer: current challenges and future perspectives, Cancer Lett, vol.320, pp.130-137, 2012.

J. M. Schmitt, S. R. Sommers, and W. Fisher, Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group, J Thorac Oncol, vol.7, pp.760-763, 2012.

M. D. Galsky, N. M. Hahn, and T. Powles, Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer, Clin Genitourin Cancer, vol.11, pp.175-181, 2013.

C. Gómez-martín, R. Salazar, and C. Montagut, A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer, Invest New Drugs, vol.31, pp.390-398, 2013.

W. L. Wang, A. Conley, D. Reynoso, L. Nolden, A. J. Lazar et al., Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor, Cancer Chemother Pharmacol, vol.67, issue.1, pp.15-24, 2011.

R. Bracci, M. E. Cascinu, and S. , Transient sunitinib resistance in gastrointestinal stromal tumors, N Engl J Med, vol.368, pp.2042-2043, 2013.

T. Martel-renoir, D. Mir, and L. M. , Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin, Cancer Res, vol.64, pp.2062-2069, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00320014

B. S. Ji, L. He, G. Liu, H. Kawahara, K. Noguchi et al., Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells, Cancer Sci, vol.77, pp.1493-1500, 2005.

T. Mizuno, M. Fukudo, and T. Terada, Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics, Drug Metab Pharmacokinet, vol.27, pp.631-639, 2012.

S. Kunimatsu, T. Mizuno, M. Fukudo, and T. Katsura, Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats, Drug Metab Dispos, vol.41, pp.1592-1597, 2013.

D. J. Hutchison, Cross resistance and collateral sensitivity studies in cancer chemotherapy, Adv Cancer Res, vol.7, pp.235-250, 1963.

D. J. Hutchison, Conference on obstacles to the control of acute leukemia. Studies on cross-resistance and collateral sensitivity (1962-1964), Cancer Res, vol.25, pp.1581-1595, 1965.

M. Cesca, F. Bizzaro, M. Zucchetti, and R. Giavazzi, Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents, Front Oncol, vol.3, p.259, 2013.

X. Y. Wu, W. Ma, K. Gurung, and C. H. Guo, Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy, J Formos Med Assoc, vol.112, pp.115-124, 2013.